WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
MOUNTAIN VIEW, Calif., April 19, 2018 -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the first quarter 2018 after the close of trading on Thursday, May 3, 2018. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 5495252. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com. A telephone replay will also be available beginning Thursday, May 3, 2018 through Friday, May 4, 2018 by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers, using conference ID: 5495252.
About IRIDEX
IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
